Proteome Sciences said this week that it has signed an agreement with Thermo Fisher Scientific providing access to patents related to its Tandem Mass Tags isobaric tagging reagents in exchange for cash and a no-cost lease from Thermo Fisher for mass spectrometry equipment.

The company plans to use that equipment to further develop its SysQuant assays for measuring activation of cancer signaling pathways with the ultimate goal of building clinical test for guiding personalized cancer treatment, Proteome Sciences COO Ian Pike, told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.